Indianapolis-based Beckman Coulter Life Sciences has acquired ValitaCell Ltd., an Ireland-based biotechnology company that creates analytical products and technologies for the biopharmaceutical industry. Financial terms of the deal were not disclosed.
ValitaCell’s technologies and products aim to reduce new therapeutics’ cost and time to market.
“ValitaCell has a proven record for delivering innovative products and we are excited to build upon our successful partnership with Beckman Coulter Life Sciences,” said Dr. Jerry Clifford, co-founder and chief executive officer of ValitaCell. “We never take for granted what our advancements can do for patients while also reducing manual workflow burdens on laboratory staff. Together with Beckman Coulter Life Sciences, we will advance our shared ambition to accelerate and enable the sustainable manufacture of innovative biological medicines to bring them to market faster.”
Beckman says ValitaCell technologies are patented in key international markets, and the company’s ValitaTiter product offers advantages over competing IgG quantification assay products such as ELISA and HPLC.
“Throughout our trusted partnership with ValitaCell, we have long admired their innovative offerings and industry expertise,” said Jason Lanie, vice president and general manager of the biotechnology business unit at Beckman Coulter Life Sciences. “Their leading portfolio of products, including ValitaTiter, Quantum, CellAi, and ChemStress Clone Robustness complement Beckman Coulter Life Sciences’ existing and future product portfolio, and are designed with the same goal of providing faster cellular analysis while decreasing the risk of errors.”
Beckman says ValitaCell locations in Dublin and Galway, Ireland will remain operational and are expected to grow as a result of business needs.
In 2019, Beckman acquired California-based liquid handling company Labcyte.